Medical_Microbiology_and_Immunology%E0%AE%AE%E0%AE%B0%E0%AF%81%E0%AE%A4%E0%AF%8D%E0%AE%A4%E0%AF%81%E0%AE%B5_%E0%AE%A8%E0%AF%81%E0%AE%A3%E0%AF%8D%E0%AE%A3%E0%AF%81%E0%AE%AF%E0%AE%BF%E0%AE%B0%E0%AE%BF%E0%AE%AF%E0%AE%BF%E0%AE%AF%E0%AE%B2%E0%AF%8D_%E0%AE%AE%E0%AE%B1%E0%AF%8D%E0%AE%B1%E0%AF%81%E0%AE%AE%E0%AF%8D_%E0%AE%A8%E0%AF%8B%E0%AE%AF%E0%AF%8D_%E0%AE%A4%E0%AE%9F%E0%AF%81%E0%AE%AA%E0%AF%8D%E0%AE%AA%E0%AE%BF%E0%AE%AF%E0%AE%B2%E0%AF%8DQ15760239
about
Cytokine kinetics of Zika virus-infected patients from acute to reconvalescent phaseHerpes simplex virus 1 DNA polymerase processivity factor UL42 inhibits TNF-α-induced NF-κB activation by interacting with p65/RelA and p50/NF-κB1Eradication of measles: remaining challengesTherapeutic vaccination and immunomodulation in the treatment of chronic hepatitis B: preclinical studies in the woodchuckMalaria and human red blood cellsModulation of translation and induction of autophagy by bacterial exoproductsAntiviral therapy for chronic hepatitis B in ChinaExploiting viral natural history for vaccine developmentInfection homeostasis: implications for therapeutic and immune programming of metabolism in controlling infectionMutational escape of CD8+ T cell epitopes: implications for prevention and therapy of persistent hepatitis virus infectionsDoxycycline as a novel strategy against bancroftian filariasis-depletion of Wolbachia endosymbionts from Wuchereria bancrofti and stop of microfilaria productionVirus-receptor interactions of coxsackie B viruses and their putative influence on cardiotropismThe functional interaction between CD98 and CD147 in regulation of virus-induced cell fusion and osteoclast formationHuman immunodeficiency virus type-1 envelope glycoprotein gp120 induces expression of fusion regulatory protein (FRP)-1/CD98 on CD4+ T cells: a possible regulatory mechanism of HIV-induced syncytium formationSingle domain antibodies: promising experimental and therapeutic tools in infection and immunityProtein tyrosine kinase activation provides an early and obligatory signal in anti-FRP-1/CD98/4F2 monoclonal antibody induced cell fusion mediated by HIV gp160Identification and localization of Chlamydia pneumoniae in the Alzheimer's brainSynthetic disaccharide-protein antigens for production of specific 04 and 09 antisera for immunofluorescence diagnosis of salmonellaPhosphorylcholine antibodies in pulmonary infectionEffect of retinoic acid on the replication of human immunodeficiency virus in HTLV-I-positive MT-4 cellsDevelopment of a high-throughput colorimetric Zika virus infection assayA new report of Nocardiopsis valliformis strain OT1 from alkaline Lonar crater of India and its use in synthesis of silver nanoparticles with special reference to evaluation of antibacterial activity and cytotoxicityBorna disease virus and schizophrenia in Surinamese immigrants to the Netherlands.Ueber die Agglutination der Pneumokokken und über die Theorieen der AgglutinationPandemic preparedness: lessons learnt from H2N2 and H9N2 candidate vaccines.Conceptional considerations for a German influenza pandemic preparedness plan.Emerging and re-emerging infectious diseases.Hand, foot and mouth disease (HFMD): emerging epidemiology and the need for a vaccine strategy.Emerging Leishmania/HIV co-infection in Africa.The "influenza vaccine"--benefit, risk, costs.Experience with the clinical development of influenza vaccines for potential pandemics.Prevalence of antibodies to European porcine influenza viruses in humans living in high pig density areas of Germany.Differential influenza H1N1-specific humoral and cellular response kinetics in kidney transplant patients.Influenza virosomes supplemented with GPI-0100 adjuvant: a potent vaccine formulation for antigen dose sparing.The threat of avian influenza A (H5N1). Part I: Epidemiologic concerns and virulence determinants.Expression profile and histological distribution of IFITM1 and IFITM3 during H9N2 avian influenza virus infection in BALB/c mice.Novel swine-origin influenza A virus in humans: another pandemic knocking at the door.Determination of serum antibodies against swine-origin influenza A virus H1N1/09 by immunofluorescence, haemagglutination inhibition, and by neutralization tests: how is the prevalence rate of protecting antibodies in humans?Comparison of pro-inflammatory cytokine expression and cellular signal transduction in human macrophages infected with different influenza A viruses.Neuraminidase inhibitor susceptibility of swine influenza A viruses isolated in Germany between 1981 and 2008.
P1433
Q22330683-324266B7-2106-446A-BEA5-23459A63ACC4Q24339512-7ED7AE1E-4A0A-4E82-9976-5FBD302B8792Q26764979-91D3B6B3-EBC7-4247-AE64-751B587D68E6Q26828598-54D94154-A60A-46FF-A914-8F1913AA9E9EQ26829795-84212560-A9E8-4B10-8746-96DC8BCC23AAQ27000440-B438B813-9E07-4CE7-87DF-8EEBF92CEA2EQ27006557-2B5C2B45-8F16-457C-842B-33C33B236675Q28081817-B64997D9-9692-4CCF-AD66-B71C2620C92AQ28083186-35A914E9-5882-4A89-AACC-6B688045AED8Q28086907-206DF08B-DC61-4A5B-BFDC-58272AB71B54Q28189876-DE051FAB-8FAC-47A4-B194-8333F9DA3D02Q28202035-179871FB-DEA1-41F2-BC55-EA330C8ECD70Q28202420-31D95288-0535-434E-A64C-E4481590DA53Q28237188-9BFE554F-0C40-48BD-B1A4-A17FECDA43F5Q28248678-2639B815-53BF-404F-AA2F-C9EEC3D06B86Q28256972-3C9CA85C-0940-4E87-8C51-3084098E7E3CQ28283487-2899918F-D945-4AC3-8BA3-99004A7DCD33Q28324198-2CDEE91C-4294-4E15-BF49-B3C8455303D6Q28332374-528DF7DA-11D5-438F-A77C-EDD902B1EBE1Q28338199-B6060509-CD4C-40D9-8525-9BDE4D88BD85Q28736791-400BFBCC-99E3-4266-86E0-645CDAEF8ABAQ28828574-F1CFA056-602A-4840-9E78-CE7D2D0EAD1EQ29354069-C380E6BE-1DEC-4979-9CFA-831A12672168Q29998882-185B7DB0-73FE-44F3-BCC6-072B0DDB50ADQ30233455-33DF8C83-974C-48A3-A105-53A0A4037334Q30233456-750CCE41-A077-4B2E-8891-F6895F56E78CQ30233468-A63A3D67-1A81-4473-A0B6-85D78F247A94Q30249022-1B0FC411-6FCA-47E6-A7A5-85097E06F544Q30329342-FDA7876E-4BD0-4ED2-A6AB-7599F3DE154FQ30332266-59F92A1F-BBC2-4DD9-A9C4-072918322C98Q30332267-5C93F668-70B4-4D58-A7DD-B5D9209A4EF8Q30353414-11DAD469-B923-4C09-8D02-1AFD7ADDE192Q30353821-A903705F-161A-4CD2-A281-918CB542AED9Q30353863-52687EF1-6792-416D-9397-056690A11A48Q30361549-8F730B1F-6104-44B4-A018-3FFD78DADC21Q30367281-2B3CAE86-619D-4534-8AB7-C73F760155B4Q30378285-4D3A6888-3901-4989-B763-5D5D7EF72425Q30385755-E2A1B170-0678-40F7-84E7-278E405CD6B8Q30394070-C1E0988E-71CD-4CB2-A08B-438F9670D526Q30404038-ECFA97F7-BE40-47BC-AF23-EFA4B55CA8ED
P1433
description
revista científica
@es
revue scientifique
@fr
rivista scientifica
@it
scientific journal
@en
wetenschappelijk tijdschrift van Springer Science+Business Media
@nl
wissenschaftliche Fachzeitschrift
@de
науковий журнал
@uk
مجلة
@ar
name
Medical Microbiology and Immunology
@ast
Medical Microbiology and Immunology
@da
Medical Microbiology and Immunology
@de
Medical Microbiology and Immunology
@en
Medical Microbiology and Immunology
@es
Medical Microbiology and Immunology
@fi
Medical Microbiology and Immunology
@fr
Medical Microbiology and Immunology
@it
Medical Microbiology and Immunology
@nb
Medical Microbiology and Immunology
@nl
type
label
Medical Microbiology and Immunology
@ast
Medical Microbiology and Immunology
@da
Medical Microbiology and Immunology
@de
Medical Microbiology and Immunology
@en
Medical Microbiology and Immunology
@es
Medical Microbiology and Immunology
@fi
Medical Microbiology and Immunology
@fr
Medical Microbiology and Immunology
@it
Medical Microbiology and Immunology
@nb
Medical Microbiology and Immunology
@nl
prefLabel
Medical Microbiology and Immunology
@ast
Medical Microbiology and Immunology
@da
Medical Microbiology and Immunology
@de
Medical Microbiology and Immunology
@en
Medical Microbiology and Immunology
@es
Medical Microbiology and Immunology
@fi
Medical Microbiology and Immunology
@fr
Medical Microbiology and Immunology
@it
Medical Microbiology and Immunology
@nb
Medical Microbiology and Immunology
@nl
P243
P3181
P1055
P1058
P1156
P1159
P1250
P1277
P1476
Medical Microbiology and Immunology
@en
P236
P243
P3181
P571
1886-01-01T00:00:00Z